Agilent divests Hycor Biomedical
This article was originally published in The Gray Sheet
Executive Summary
Life sciences firm Agilent Technologies divests its Hycor in vitro diagnostics business to private equity firm Linden LLC for undisclosed terms on Feb. 3. Hycor, which makes allergy, autoimmune and urinalysis tests, was acquired by Agilent in 2007 as part of its purchase of Stratagene. It is a "profitable and growing business but it does not fit the core focus of our life science business," Agilent explained (1"The Gray Sheet" June 11, 2007)